MedTrace Logo

Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES

NCT01291745 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2011-02-08

No results posted yet for this study

Summary

The present study is designed to determine the mutational status of markers (TET2 and PLCb2, cytogenetic aberrations) together with methylation status of the above genes using bone marrow and matched buccal cell samples from MDS patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine). All patients included in the study will be followed for at least 2 years.

Conditions

Sponsors & Collaborators

  • Fondazione Amelia Scorza Onlus

    lead OTHER

Principal Investigators

  • Fortunato Morabito, MD · Unità Operativa Complessa di Ematologia- Azienda Ospedaliera di Cosenza - Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-09-30
Completion
2015-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01291745 on ClinicalTrials.gov